Sugi Predict

Sugi Predict / Compounds / SCHEMBL7070567

SCHEMBL7070567

SCHEMBL7070567

Clc1cc2c(s1)SN=C(NCC1CCCCC1)N2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 1/20 0.35
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ GRM4 Q14833 1/20 0.33
▸ IDO1 P14902 1/20 0.32
▸ TDO2 P48775 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ HTR3A P46098 1/20 0.31
▸ HRH4 Q9H3N8 1/20 0.31
▸ PI4KB Q9UBF8 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.30
▸ ASPH Q12797 1/20 0.30
▸ RIOX2 Q8IUF8 1/20 0.30
▸ KDM8 Q8N371 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7069732 0.81 KMT2A (0.35) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL7006346 0.80 — —
SCHEMBL7068004 0.79 HTR5A (0.35) MEN1KMT2AABCC8KCNJ11
SCHEMBL8652279 0.77 HTR3A (0.39) MEN1KMT2AGRM4HTR3AHRH4
SCHEMBL7071984 0.76 HTR5A (0.37) MEN1KMT2AABCC8KCNJ11
SCHEMBL7069104 0.76 ESR1 (0.36) —
SCHEMBL7067549 0.76 — —
SCHEMBL7067483 0.76 ABCC8 (0.31) ABCC8KCNJ11
SCHEMBL7074727 0.76 ABCC8 (0.40) CHRM4MEN1KMT2ACA2HTR3A
SCHEMBL7065748 0.75 KDM4E (0.31) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 — — WO claimed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO claimed
WO-2003045955-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO claimed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 — — WO claimed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 — — WO claimed
EP-1000066-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-05-17 — — EP claimed
WO-1999003861-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-01-28 — — WO claimed
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 — — WO disclosed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO disclosed
WO-2003045955-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 — — WO disclosed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 — — WO disclosed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 — — WO disclosed
EP-1000066-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-05-17 — — EP disclosed
WO-1999003861-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-01-28 — — WO disclosed